Definium Therapeutics is trading 4.22% up at $38.38 after investors continued responding to positive Phase 3 Panorama results for DT120 in generalized anxiety disorder.
- The study met its primary and key secondary endpoints, showing a statistically significant 5.1-point placebo-adjusted HAM-A reduction at Week 12 after one 100 µg dose.
- No new safety signals were reported, supporting the company’s planned NDA filing.